These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25302109)

  • 21. A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa
    Kim HJ; Shim Y; Han HJ; Kim BC; Park KH; Moon SY; Choi SH; Yang DW; Yoon B; Kim EJ; Jeong JH; Han SH
    Neurol Ther; 2023 Aug; 12(4):1221-1233. PubMed ID: 37245175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
    Delrieu J; Piau A; Caillaud C; Voisin T; Vellas B
    CNS Drugs; 2011 Mar; 25(3):213-26. PubMed ID: 21323393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
    Owen RT
    Drugs Today (Barc); 2016 Apr; 52(4):239-48. PubMed ID: 27252988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative tolerability of Alzheimer's disease treatments.
    Alva G; Cummings JL
    Psychiatry (Edgmont); 2008 Nov; 5(11):27-36. PubMed ID: 19724715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.
    Koola MM; Nikiforuk A; Pillai A; Parsaik AK
    J Geriatr Care Res; 2018; 5(2):57-67. PubMed ID: 30984874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
    Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
    J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.
    Tampi RR; van Dyck CH
    Neuropsychiatr Dis Treat; 2007 Apr; 3(2):245-58. PubMed ID: 19300557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of memantine for the treatment of Alzheimer's disease.
    Matsunaga S; Kishi T; Nomura I; Sakuma K; Okuya M; Ikuta T; Iwata N
    Expert Opin Drug Saf; 2018 Oct; 17(10):1053-1061. PubMed ID: 30222469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials.
    Tsoi KK; Chan JY; Chan FC; Hirai HW; Kwok TC; Wong SY
    Clin Pharmacol Ther; 2019 Jan; 105(1):121-130. PubMed ID: 29717478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
    Cappell J; Herrmann N; Cornish S; Lanctôt KL
    CNS Drugs; 2010 Nov; 24(11):909-27. PubMed ID: 20932064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease.
    Li DD; Zhang YH; Zhang W; Zhao P
    Front Neurosci; 2019; 13():472. PubMed ID: 31156366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.
    Klinger T; Ibach B; Schoenknecht P; Kamleiter M; Silver G; Schroeder J; Mielke R
    Curr Med Res Opin; 2005 May; 21(5):723-32. PubMed ID: 15969871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.